Open Access<p>Polymorphisms of <em>CYP2C9*2</em>, <em>CYP2C9*3</em> and <em>VKORC1</em> genes related to time in therapeutic range in patients with atrial fibrillation using warfarin</p>
Author(s) -
Maria Mariana Barros Melo da Silveira,
Leiliandry de Araújo Melo,
Filipe Maia Ferreira Gomes,
Leonardo José de Cupertino Barreto da Rocha Andrade,
I.P. Serur,
Isabelle Cecília de Vasconcellos Piscoya,
Raposo Marina Gueiros,
Kleyton Palmeira do Ó,
Raul Emídio de Lima,
Victor Arthur Eulálio Brasileiro,
Luydson Richardson Silva Vasconcelos,
Dário Celestino Sobral Filho
Publication year - 2019
Publication title -
application of clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.879
H-Index - 32
ISSN - 1178-704X
DOI - 10.2147/tacg.s197316
Subject(s) - medicine , biology
Warfarin continues to be the most widely used anticoagulant in clinical practice around the world for the prevention of thromboembolic events in patients with atrial fibrillation (AF). The evaluation of the quality of anticoagulation control, estimated by time in therapeutic range (TTR), is accepted as a good method to evaluate the quality of anticoagulation. The variability of TTR can be explained by the presence of variants of the CYP2C9 and VKORC1 genes.